Published in Biol Direct on September 12, 2011
Gag-Pol processing during HIV-1 virion maturation: a systems biology approach. PLoS Comput Biol (2013) 0.89
A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns. BMC Syst Biol (2013) 0.77
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
HIV-1 pathogenesis. Nat Med (2003) 2.88
Where does HIV live? N Engl J Med (2004) 1.96
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Current trends in the estimation of Michaelis-Menten parameters. Anal Biochem (1980) 1.63
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr (2000) 1.41
Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol (1974) 1.37
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol (2009) 1.33
Quantitative intracellular kinetics of HIV type 1. AIDS Res Hum Retroviruses (1999) 1.31
Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency. Trends Pharmacol Sci (2001) 1.22
Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS (1999) 1.17
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. Curr Opin Infect Dis (2009) 1.03
Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther (2009) 1.02
New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect (2003) 1.02
Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs. J Biol Chem (1994) 0.97
Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther (2009) 0.96
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem (2002) 0.95
Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus. Proc Natl Acad Sci U S A (2006) 0.94
Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins. J Virol Methods (2009) 0.87
In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol (2009) 0.87
The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother (2000) 0.85
Thermodynamics of A:G mismatch poly(dG) synthesis by human immunodeficiency virus 1 reverse transcriptase. J Biol Chem (1991) 0.83
Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine. Biochem Pharmacol (1998) 0.82
Novel strategies to treat antiretroviral-naive HIV-infected patients. J Antimicrob Chemother (2009) 0.79
Mistranslation-induced protein misfolding as a dominant constraint on coding-sequence evolution. Cell (2008) 6.91
Why highly expressed proteins evolve slowly. Proc Natl Acad Sci U S A (2005) 6.19
A single determinant dominates the rate of yeast protein evolution. Mol Biol Evol (2005) 4.85
Thermodynamic prediction of protein neutrality. Proc Natl Acad Sci U S A (2005) 3.30
The evolutionary consequences of erroneous protein synthesis. Nat Rev Genet (2009) 3.11
A universal trend of reduced mRNA stability near the translation-initiation site in prokaryotes and eukaryotes. PLoS Comput Biol (2010) 2.57
The traveling-wave approach to asexual evolution: Muller's ratchet and speed of adaptation. Theor Popul Biol (2007) 2.07
Quasispecies theory in the context of population genetics. BMC Evol Biol (2005) 2.02
Translationally optimal codons associate with structurally sensitive sites in proteins. Mol Biol Evol (2009) 1.96
T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis (2009) 1.94
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89
Adaptive radiation from resource competition in digital organisms. Science (2004) 1.86
Thermodynamics of neutral protein evolution. Genetics (2006) 1.83
Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog (2007) 1.81
Structural determinants of the rate of protein evolution in yeast. Mol Biol Evol (2006) 1.75
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
Avida: a software platform for research in computational evolutionary biology. Artif Life (2004) 1.62
On the conservative nature of intragenic recombination. Proc Natl Acad Sci U S A (2005) 1.37
Density-dependent selection in vesicular stomatitis virus. J Virol (2004) 1.37
Co-infection weakens selection against epistatic mutations in RNA viruses. Genetics (2004) 1.31
The stochastic edge in adaptive evolution. Genetics (2008) 1.30
The look-ahead effect of phenotypic mutations. Biol Direct (2008) 1.28
The relationship between relative solvent accessibility and evolutionary rate in protein evolution. Genetics (2011) 1.25
Stability and the evolvability of function in a model protein. Biophys J (2004) 1.21
Maximum allowed solvent accessibilites of residues in proteins. PLoS One (2013) 1.18
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis (2008) 1.15
Integrating sequence variation and protein structure to identify sites under selection. Mol Biol Evol (2012) 1.15
Contact density affects protein evolutionary rate from bacteria to animals. J Mol Evol (2008) 1.10
Contact heterogeneity and phylodynamics: how contact networks shape parasite evolutionary trees. Interdiscip Perspect Infect Dis (2010) 1.07
Lethal mutagenesis of bacteria. Genetics (2008) 1.05
Effects of population size and mutation rate on the evolution of mutational robustness. Evolution (2007) 1.03
The phenotype-fitness map in experimental evolution of phages. PLoS One (2011) 1.03
Experiments on the role of deleterious mutations as stepping stones in adaptive evolution. Proc Natl Acad Sci U S A (2013) 1.03
Modeling coding-sequence evolution within the context of residue solvent accessibility. BMC Evol Biol (2012) 1.02
Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. Antivir Ther (2009) 1.02
Detecting positive and purifying selection at synonymous sites in yeast and worm. Mol Biol Evol (2010) 1.00
Selection for mutational robustness in finite populations. J Theor Biol (2006) 0.99
Breaking proteins with mutations: threads and thresholds in evolution. Mol Syst Biol (2007) 0.98
Sinonasal anatomic variants and asthma are associated with faster development of chronic rhinosinusitis in patients with allergic rhinitis. Int Forum Allergy Rhinol (2013) 0.97
Translationally optimal codons associate with aggregation-prone sites in proteins. Proteomics (2010) 0.96
Predicting evolutionary site variability from structure in viral proteins: buriedness, packing, flexibility, and design. J Mol Evol (2014) 0.95
Cross-species comparison of site-specific evolutionary-rate variation in influenza haemagglutinin. Philos Trans R Soc Lond B Biol Sci (2013) 0.95
Reduced mRNA secondary-structure stability near the start codon indicates functional genes in prokaryotes. Genome Biol Evol (2011) 0.95
Reduced stability of mRNA secondary structure near the translation-initiation site in dsDNA viruses. BMC Evol Biol (2011) 0.94
PeptideBuilder: A simple Python library to generate model peptides. PeerJ (2013) 0.93
Rapid adaptive amplification of preexisting variation in an RNA virus. J Virol (2008) 0.93
Risk factors for development of chronic rhinosinusitis in patients with allergic rhinitis. Int Forum Allergy Rhinol (2012) 0.92
Relationship between protein thermodynamic constraints and variation of evolutionary rates among sites. Phys Biol (2015) 0.92
Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. AIDS Res Hum Retroviruses (2011) 0.90
Incongruent fitness landscapes, not tradeoffs, dominate the adaptation of vesicular stomatitis virus to novel host types. J Gen Virol (2010) 0.90
Methods of modelling viral disease dynamics across the within- and between-host scales: the impact of virus dose on host population immunity. Philos Trans R Soc Lond B Biol Sci (2010) 0.86
Membrane environment imposes unique selection pressures on transmembrane domains of G protein-coupled receptors. J Mol Evol (2013) 0.85
Detecting clusters of mutations. PLoS One (2008) 0.84
Principal-oscillation-pattern analysis of gene expression. PLoS One (2012) 0.84
Eigen-genomic system dynamic-pattern analysis (ESDA): modeling mRNA degradation and self-regulation. IEEE/ACM Trans Comput Biol Bioinform (2011) 0.83
Does mutational robustness inhibit extinction by lethal mutagenesis in viral populations? PLoS Comput Biol (2010) 0.83
Socioeconomic disparities in the presentation of acute bacterial sinusitis complications in children. Laryngoscope (2013) 0.82
Amino-acid site variability among natural and designed proteins. PeerJ (2013) 0.82
Lethal mutagenesis in a structured environment. J Theor Biol (2009) 0.82
Specific and nonspecific host adaptation during arboviral experimental evolution. J Mol Microbiol Biotechnol (2012) 0.81
Genomic evolution of vesicular stomatitis virus strains with differences in adaptability. J Virol (2010) 0.81
RNaseIII and T4 polynucleotide Kinase sequence biases and solutions during RNA-seq library construction. Biol Direct (2013) 0.80
Temporal and spatial alterations in mutant swarm size of St. Louis encephalitis virus in mosquito hosts. Infect Genet Evol (2011) 0.78
Evolution of resource competition between mutually dependent digital organisms. Artif Life (2004) 0.78
Congruent evolution of fitness and genetic robustness in vesicular stomatitis virus. J Virol (2013) 0.77
A linear relationship between fitness and the logarithm of the critical bottleneck size in vesicular stomatitis virus populations. J Virol (2008) 0.77
Tradeoff between short-term and long-term adaptation in a changing environment. Phys Rev E Stat Nonlin Soft Matter Phys (2005) 0.77
Long-term control of viral replication in a Group O, human immunodeficiency virus type 1-infected individual. AIDS Res Hum Retroviruses (2014) 0.76
Digital evolution in time-dependent fitness landscapes. Artif Life (2004) 0.76
Frequency-Dependent Selection in a Periodic Environment. Physica A (2007) 0.76
Interactions between evolutionary processes at high mutation rates. Evolution (2012) 0.76
The role of environmental factors on the evolution of phenotypic diversity in vesicular stomatitis virus populations. J Gen Virol (2012) 0.75
Supplementary materials need the right format. Nature (2004) 0.75